BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33448385)

  • 1. In vivo magnetic resonance spectroscopy in the brain of Cdkl5 null mice reveals a metabolic profile indicative of mitochondrial dysfunctions.
    Carli S; Chaabane L; Butti C; De Palma C; Aimar P; Salio C; Vignoli A; Giustetto M; Landsberger N; Frasca A
    J Neurochem; 2021 May; 157(4):1253-1269. PubMed ID: 33448385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.
    Galvani G; Mottolese N; Gennaccaro L; Loi M; Medici G; Tassinari M; Fuchs C; Ciani E; Trazzi S
    J Neuroinflammation; 2021 Jul; 18(1):155. PubMed ID: 34238328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescue of prepulse inhibition deficit and brain mitochondrial dysfunction by pharmacological stimulation of the central serotonin receptor 7 in a mouse model of CDKL5 Deficiency Disorder.
    Vigli D; Rusconi L; Valenti D; La Montanara P; Cosentino L; Lacivita E; Leopoldo M; Amendola E; Gross C; Landsberger N; Laviola G; Kilstrup-Nielsen C; Vacca RA; De Filippis B
    Neuropharmacology; 2019 Jan; 144():104-114. PubMed ID: 30326240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder.
    Fuchs C; Gennaccaro L; Ren E; Galvani G; Trazzi S; Medici G; Loi M; Conway E; Devinsky O; Rimondini R; Ciani E
    Neuropharmacology; 2020 May; 167():107746. PubMed ID: 31469994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.
    Fuchs C; Medici G; Trazzi S; Gennaccaro L; Galvani G; Berteotti C; Ren E; Loi M; Ciani E
    Brain Pathol; 2019 Sep; 29(5):658-674. PubMed ID: 30793413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
    Tang S; Terzic B; Wang IJ; Sarmiento N; Sizov K; Cui Y; Takano H; Marsh ED; Zhou Z; Coulter DA
    Nat Commun; 2019 Jun; 10(1):2655. PubMed ID: 31201320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A GABA
    Gennaccaro L; Fuchs C; Loi M; Roncacè V; Trazzi S; Ait-Bali Y; Galvani G; Berardi AC; Medici G; Tassinari M; Ren E; Rimondini R; Giustetto M; Aicardi G; Ciani E
    Neurobiol Dis; 2021 Jun; 153():105304. PubMed ID: 33621640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo.
    Trovò L; Fuchs C; De Rosa R; Barbiero I; Tramarin M; Ciani E; Rusconi L; Kilstrup-Nielsen C
    Neurobiol Dis; 2020 May; 138():104791. PubMed ID: 32032735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder.
    Terzic B; Cui Y; Edmondson AC; Tang S; Sarmiento N; Zaitseva D; Marsh ED; Coulter DA; Zhou Z
    Neurobiol Dis; 2021 Jan; 148():105176. PubMed ID: 33197557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.
    Yennawar M; White RS; Jensen FE
    J Neurosci; 2019 Jun; 39(24):4814-4828. PubMed ID: 30952813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
    Jhang CL; Lee HY; Chen JC; Liao W
    Hum Mol Genet; 2020 Aug; 29(14):2408-2419. PubMed ID: 32588892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
    Wang HT; Zhu ZA; Li YY; Lou SS; Yang G; Feng X; Xu W; Huang ZL; Cheng X; Xiong ZQ
    Epilepsia; 2021 Feb; 62(2):517-528. PubMed ID: 33400301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormalities of mitochondrial dynamics and bioenergetics in neuronal cells from CDKL5 deficiency disorder.
    Van Bergen NJ; Massey S; Stait T; Ellery M; Reljić B; Formosa LE; Quigley A; Dottori M; Thorburn D; Stroud DA; Christodoulou J
    Neurobiol Dis; 2021 Jul; 155():105370. PubMed ID: 33905871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and Synaptic Bases of CDKL5 Disorder.
    Zhu YC; Xiong ZQ
    Dev Neurobiol; 2019 Jan; 79(1):8-19. PubMed ID: 30246934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mGluR5 PAMs rescue cortical and behavioural defects in a mouse model of CDKL5 deficiency disorder.
    Gurgone A; Pizzo R; Raspanti A; Chiantia G; Devi S; Comai D; Morello N; Pilotto F; Gnavi S; Lupori L; Mazziotti R; Sagona G; Putignano E; Nocentini A; Supuran CT; Marcantoni A; Pizzorusso T; Giustetto M
    Neuropsychopharmacology; 2023 May; 48(6):877-886. PubMed ID: 35945276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteolin Treatment Ameliorates Brain Development and Behavioral Performance in a Mouse Model of CDKL5 Deficiency Disorder.
    Tassinari M; Mottolese N; Galvani G; Ferrara D; Gennaccaro L; Loi M; Medici G; Candini G; Rimondini R; Ciani E; Trazzi S
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with FRAX486 rescues neurobehavioral and metabolic alterations in a female mouse model of CDKL5 deficiency disorder.
    Fuchs C; Cosentino L; Urbinati C; Talamo MC; Medici G; Quattrini MC; Mottolese N; Pietraforte D; Fuso A; Ciani E; De Filippis B
    CNS Neurosci Ther; 2022 Nov; 28(11):1718-1732. PubMed ID: 35932179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant mitochondrial function in patient-derived neural cells from CDKL5 deficiency disorder and Rett syndrome.
    Jagtap S; Thanos JM; Fu T; Wang J; Lalonde J; Dial TO; Feiglin A; Chen J; Kohane I; Lee JT; Sheridan SD; Perlis RH
    Hum Mol Genet; 2019 Nov; 28(21):3625-3636. PubMed ID: 31518399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder.
    Fuchs C; Gennaccaro L; Trazzi S; Bastianini S; Bettini S; Lo Martire V; Ren E; Medici G; Zoccoli G; Rimondini R; Ciani E
    Neural Plast; 2018; 2018():9726950. PubMed ID: 29977282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder.
    Katayama S; Sueyoshi N; Inazu T; Kameshita I
    Neural Plast; 2020; 2020():6970190. PubMed ID: 32587608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.